Initially, Bydureon required a complicated reconstitution
Full analysis #GLP1 #EmployeeBenefits #HealthcareCosts #WorkforceHealth #Aon Farheen Dam Doug Melton Lisa Stevens Laura Rissover Liz Parr Lindsay Dower, MHA Kembre Roberts, PhD Workforce-Focused Analysis on GLP-1s: Phase Two Findings aon.com To view or add a comment, sign in Novo Nordisks FDA-approved Wegovy pill, as highlighted by Ferrin Williams, PharmD MBA, marks a major shift in obesity careintroducing an oral GLP-1 option that could expand access, improve adherence, and reshape how clinicians manage chronic weight conditions
This is particularly relevant for time-sensitive supplements like iron, thyroid medications, and certain vitamins that have specific absorption requirements
The growth in the forecast period can be attributed to growing obesity population, expanding approval for cardiovascular risk reduction, innovation in oral and combination therapies, increased penetration in emerging markets, rising patient preference for weight loss benefits
However, dosing may be tailored depending on patient sensitivity to bitterness and to increased susceptibility to mild GI side effects